Exabis Library
Welcome to the e-CCO Library!
P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn’s disease refractory or intolerant to anti-TNF: a multicentre Italian study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P415: Dose escalation of adalimumab and related prognostic factors in patients with Crohn's disease treated with adalimumab maintenance therapy: A single-centre, five-year cohort study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P415: Improving food‐related quality of life in Inflammatory Bowel Disease with a novel web-based intervention: a randomised controlled feasibility trial
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P415: Paradoxical onset of Takayasu’s arteritis in patients with inflammatory bowel disease treated with anti-tumour necrosis factor-α agents
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P415: Predictive factors of a subsequent ano-perineal abscess in patients with fistulising ano-perineal Crohn’s disease in remission
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P415: Real-world data in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional LISTEN II study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P415: Therapeutic drug monitoring of thiopurines in the management of Asian patients with inflammatory bowel disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P415: Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P416 Results of the first paediatric randomised controlled trial of faecal microbiota transplant for ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P416: Addition of oral antibiotics to mechanical bowel preparation significantly improves anastomotic healing after ileocolic resection for Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P416: An online educational portal is effective in improving knowledge regarding reproduction and IBD
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P416: Faecal calprotectin can predict mucosal healing in patients with inflammatory bowel diseases treated with vedolizumab: a prospective single-centre study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P416: Metabolite measurement for thiopurine therapy in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P416: Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P416: The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United Kingdom.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P416: Use of DXA in children with Inflammatory Bowel Disease – a large single centre study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P417 Do ACE inhibitors and angiotensin II receptor blockers improve disease outcomes in inflammatory bowel disease?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P417: 10 years of endoscopic therapy of symptomatic Crohn’s disease stenoses: a retrospective analysis of long-term results
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P417: Crohn disease recurrences: Nothing new under the sun?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P417: Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM